Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients

by Wang, Y, Choueiri, T K, Lee, J-L, Tan, M-H, Rha, S Y, North, S A, Kollmannsberger, C K, McDermott, D F, Heng, D Y C
Published 2014

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors

by Kaymakcalan, M D, Je, Y, Sonpavde, G, Galsky, M, Nguyen, P L, Heng, D Y C, Richards, C J, Choueiri, T K
Published 2013

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

by Ko, J J, Choueiri, T K, Rini, B I, Lee, J-L, Kroeger, N, Srinivas, S, Harshman, L C, Knox, J J, Bjarnason, G A, MacKenzie, M J, Wood, L, Vaishampayan, U N, Agarwal, N, Pal, S K, Tan, M-H, Rha, S Y, Yuasa, T, Donskov, F, Bamias, A, Heng, D Y C
Published 2014

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

by Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., Azad, A. A., Eigl, B. J., Heng, D. Y. C., Joshua, A. M., de Bono, J. S., Scher, H. I.
Published 2016